Long-Term Proactive Treatment of Plaque Psoriasis with Calcipotriene/Betamethasone Dipropionate Foam Prolongs Remission and Reduces Relapses Irrespective of Patient Baseline Characteristics

Funding

This study and the journal's Rapid Service Fee were funded by LEO Pharma, Ballerup, Denmark. Richard B. Warren is supported by the Manchester NIHR Biomedical Research Centre.

Medical Writing, Editorial, and Other Assistance

Medical writing support for the development of this manuscript, under the direction of the authors, was provided by Gautam Bijur, PhD, and editing support by Dena McWain, both of Ashfield MedComms, an Ashfield Health company, and funded by LEO Pharma, Ballerup, Denmark.

Authorship

All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Author Contributions

Mark G. Lebwohl, Kim A. Papp, Marie Holst Mørch, Marie Y. Jablonski Bernasconi, and Richard B. Warren contributed to the study conception and design. Material preparation, data collection, and analysis were performed by Marie Holst Mørch. The first draft of the manuscript was written by Mark G. Lebwohl and Marie Holst Mørch, and Mark G. Lebwohl, Kim A. Papp, Marie Holst Mørch, Marie Y. Jablonski Bernasconi, and Richard B. Warren commented on previous versions of the manuscript. Mark G. Lebwohl, Kim A. Papp, Marie Holst Mørch, Marie Y. Jablonski Bernasconi, and Richard B. Warren read and approved the final manuscript.

Disclosures

Mark G. Lebwohl is an employee of Mount Sinai and receives research funds from AbbVie Inc., Amgen, Arcutis Biotherapeutics, Boehringer Ingelheim, Dermavant Sciences Ltd., Eli Lilly and Company, Incyte, Janssen Research & Development, LLC, LEO Pharma, Ortho Dermatologics, Pfizer, and UCB, Inc., and is a consultant for Aditum Bio, Allergan, Almirall, Arcutis Biotherapeutics, Avotres Therapeutics, Birch-BioMed Inc., BMD Skincare, Boehringer Ingelheim, Bristol-Myers Squibb, Cara Therapeutics, Castle Biosciences, CorEvitas, Dermavant Sciences, Evelo, Facilitate International Dermatologic Education, Foundation for Research and Education in Dermatology, Inozyme Pharma, Kyowa Kirin, LEO Pharma, Meiji Seika Pharma, Menlo, Mitsubishi, Neuroderm, Pfizer, Promius/Dr. Reddy’s Laboratories, Serono, Theravance, and Verrica. Kim A. Papp has received honoraria for advisory board, speaker, and consultant services from AbbVie Inc, Actelion, Allergan, Amgen, Anacor Pharmaceuticals Inc, Astellas Pharma, Avillion, Bausch Health, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Dermira, Eli Lilly and Company, EMD Serono, Galderma, Gilead, GlaxoSmithKline, Incyte Corporation, Janssen Pharmaceuticals, Kyowa Kirin, LEO Pharma, Meiji Seika, Merck, Novartis, Pfizer, Regeneron Pharmaceuticals, Roche, Sanofi Genzyme, Sun Pharmaceutical Industries Ltd, Takeda Pharmaceutical Company, UCB Pharma, and Vertex Pharmaceuticals and has received research grants for investigator services from AbbVie Inc., Actelion, Allergan, Amgen, Anacor Pharmaceuticals Inc., Astellas Pharma, Avillion, Bausch Health, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Dermira, Eli Lilly and Company, EMD Serono, Galderma, Gilead, GlaxoSmithKline, Incyte Corp., Janssen Pharmaceuticals, Kyowa Kirin, LEO Pharma, Meiji Seika, Merck, Novartis, Pfizer, Regeneron Pharmaceuticals, Roche, Sanofi Genzyme, Sun Pharmaceutical Industries Ltd, Takeda Pharmaceutical Company, and UCB Pharma. Marie Holst Mørch and Marie Y. Jablonski Bernasconi are employees of LEO Pharma. Richard B. Warren receives research grants from AbbVie, Almirall, Amgen, Celgene, Janssen, Eli Lilly and Company, LEO Pharma, Medac, Novartis, Pfizer, and UCB and consulting fees from AbbVie, Almirall, Amgen, Arena, Astellas, Avillion, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, DiCE, GlaxoSmithKline, Janssen, Eli Lilly and Company, LEO Pharma, Medac, Novartis, Pfizer, Sanofi, Sun Pharma, UCB, and UNION.

Compliance with Ethics Guidelines

This was a post hoc analysis of the PSO LONG study (NCT02899962). A statement of ethics was provided for the primary study upon which this post hoc analysis is based. Approval for the clinical trial protocol was obtained from the relevant institutional review boards or independent ethics committees and regulatory authorities for each participating site before patient enrollment. All patients provided written informed consent. The trial was conducted in accordance with Good Clinical Practice and Ethical Principles for Medical Research Involving Human Subjects.

Data Availability

Because this was a post hoc analysis, data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

留言 (0)

沒有登入
gif